AIDSWEEKLY Plus; Monday, September 15, 2003
Staff Medical Writers

HAART became widespread in more-developed countries from 1996 onward, and has improved the prognosis of HIV-1 infection. However, not enough is known about how to predict the prognosis of people with HIV-1 infection starting HAART.

The initial measurement of specific immune response cells (CD4 cells) and viral load at the time patients start HAART is related to HIV/AIDS progression; in general, the lower the CD4 cell count and higher the viral load, the worse the prognosis. As virus concentrations decline quickly in many patients, with substantial increases in CD4 cell counts within months of starting HAART, the accuracy of predictions of disease progression might be improved by accounting for initial response to therapy. This response might allow the early identification of patients who are at a high risk of progression and who might benefit from modification or intensification of therapy.

Matthias Egger from the University of Bern, Switzerland, and colleagues writing in the Lancet analyzed 13 follow-up studies from Europe and North America, which included more than 9000 patients receiving HAART (with a minimum of three drugs) for the first time. Overall, 152 patients died and 874 developed AIDS.

As expected, patients with higher CD4 counts had lower risks of AIDS or death 6 months after starting HAART than patients with low CD4 counts (for example, lower than 100 CD4 cells per milliliter); similarly, lower viral load was indicative of a better prognosis. Measurements of CD4 cells and viral load at the time of starting HAART were not, however, indicative of prognosis once the 6-month assessment had been taken into account.

Egger said, "At 6 months after starting HAART, the current CD4 cell count and viral load, but not the values before the start of therapy, are strongly associated with subsequent disease progression. Our findings should inform guidelines on when to modify HAART in this group of patients who had not previously received antiretroviral therapy" (The Antiretroviral Therapy (ART) Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003 Aug 30;362(9385):679-86.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Egger M, Chene G, Sterne JA, et al., "Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies", Lancet. 2003 Aug 30;362(9385):679-86

PubMED Related articles Search

030915
AW030909

Copyright © 2003 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.